Xcout Intel
Verge Genomics
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Subscribe to see Verge Genomics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Verge Genomics at a glance
Verge Genomics is a biotech company headquartered in United States. Xcout tracks 2 named people at Verge Genomics, including Alice Zhang (CEO). Xcout recorded 1 job posting from Verge Genomics in the last 90 days.
Verge Genomics leadership
- Alice ZhangCEO
- Emily RipkaHead of Product & Engineering
Hiring at Verge Genomics
Xcout recorded 1 job posting from Verge Genomics in the last 90 days, from a hiring record Xcout has kept since May 2026.
The weekly hiring trend, the roles and locations behind it — see Verge Genomics's hiring signals →
Verge Genomics competitors
A few of Verge Genomics's closest competitors — see the full list of competitors and alternatives →
Deep Genomics is a biotechnology research company that collaborates across disciplines to solve complex molecular design challenges. The company's corporate headquarters are located in Toronto, Ontario, Canada, a hub for innovation.
GATC Health Corp. is a biotechnology company that uses artificial intelligence, genomics, and toxicology data to discover and develop therapeutics and predict drug safety. Its work is aimed at pharmaceutical and biotechnology partners as well as patients needing treatments for serious diseases.
Variant Bio, Inc. is a biotechnology company that uses human genomic diversity and population genetics to discover therapeutic targets and develop medicines. It works with researchers, healthcare and biotechnology partners, and genetically diverse communities to study traits associated with health and disease.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Pathos AI, Inc. is an artificial-intelligence-driven biopharmaceutical company that uses multimodal patient and biological data to discover and develop precision medicines. Its work is focused primarily on oncology and serves patients with serious diseases through pharmaceutical and healthcare partnerships.
Get Verge Genomics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Verge Genomics in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access